A systematic review and meta-analysis of metformin among patients with polycystic ovary syndrome undergoing assisted reproductive technology procedures

作者：Huang Xiaman; Wang Pin; Tal Reshef; Ly Fang; Li Yuanyuan; Zhang Xiaomei^*

来源：International Journal of Gynecology & Obstetrics, 2015, 131(2): 111-116.

DOI：10.1016/j.ijgo.2015.04.046

• Assisted reproductive technology
• Metformin
• Polycystic ovary syndrome
• Pregnancy
• Systematic review

Background: Metformin is used among patients with polycystic ovary syndrome (PCOS), but findings for its effects on outcomes of assisted reproductive technology (ART) have been conflicting. Objectives: To compare ART outcomes among women with PCOS who were and were not given metformin. Search strategy: Databases were searched for reports published in English between 2002 and 2013, using combinations of the terms "polycystic ovary syndrome," "PCOS," "insulin-sensitizing," and "metformin." Selection criteria: Randomized controlled trials of metformin versus placebo among women with PCOS undergoing ART were included if they assessed rates of pregnancy, live birth, spontaneous abortion, multiple pregnancy, and/or ovarian hyperstimulation syndrome (OHSS). Data collection and analysis: Data were extracted from included studies. The Mantel-Haenzel random-effects model was used for meta-analyses. Main results: Twelve studies (1516 participants) were included. No significant differences were recorded between metformin and placebo groups for rates of pregnancy (risk ratio [RR] 1.11,95% CI 0.92-133), live birth (RR 1.12,0.92-136), spontaneous abortion (RR 1.00,0.60-1.67), or multiple pregnancy (RR 0.96, 0.47-1.96). However, OHSS rate was significantly lower among patients who received metformin than among those who received placebo (RR 0.44, 026-0.77). Conclusions: Metformin does not improve ART outcomes among patients with PCOS, but does significantly reduce their risk of OHSS.

• 出版日期2015-11
• 单位扬州大学